T2 Biosystems regains compliance with Nasdaq’s market value requirement

T2 Biosystems announced that it received written notice from the NASDAQ Stock Market on August 8, 2023 informing the Company that it has regained compliance with the market value of listed securities requirement, as set forth in Nasdaq Listing Rule 5550(b)(2) for continued listing on the NASDAQ Capital Market. As previously reported, T2 Biosystems was notified by the NASDAQ on November 22, 2022 that it was not in compliance with the NASDAQ’s Capital Market requirement because it failed to maintain a MVLS of at least $35 million for a period of 30 consecutive business days. To regain compliance with the Rule, the Company was required to maintain a MVLS of at least $35 million for at least 10 consecutive trading days. This requirement was met on August 7, 2023, the tenth consecutive trading day when the MVLS was at least $35 million.